Avance Clinical Client Immunic, Inc. Announced Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function
- 2020年09月04日 16:00:00
- テクノロジー
- JCN Newswire
Immunic Therapeutics (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases.
According to the public announcement released by Immunic Therapeutics on 20 August 2020:
> IMU-856, an orally available, small molecule modulator, serves as a transcriptional regulator of intestinal barrier function. Based on preclinical data, the compound appears to represent a novel and potentially paradigm-shifting approach to the treatment of gastrointestinal diseases by potentially restoring intestinal barrier function while maintaining immunocompetency.
> Immunic's Australian subsidiary, Immunic Australia Pty Ltd., received approval from the Bellberry Human Research Ethics Committee in Australia to conduct a phase 1 clinical trial of IMU-856 under the Clinical Trial Notification (CTN) scheme of the Australian Therapeutic Goods Administration (TGA). The phase 1 clinical program includes single and multiple ascending dose parts in healthy volunteers. Subsequently, Immunic also plans to extend this program to assess biomarker, safety and drug trough levels in patients with diarrhea-predominant irritable bowel syndrome, ulcerative colitis and Crohn's disease.
Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, noted, "Current treatments for many gastrointestinal conditions focus on inhibiting inflammation and do not directly address impaired intestinal barrier function. In contrast, IMU-856 appears to have a unique targeted ability to strengthen and thereby normalize this function, potentially avoiding the bacterial triggers which can occur when the intestinal barrier is impaired. Moreover, because this approach appears to avoid any detrimental effects on the immune system, we believe that IMU-856 has the potential to change the treatment paradigm for gastrointestinal diseases."
Avance Clinical Chief Scientific Officer Gabriel Kremmidiotis PhD, BSC Hon said, "We consider ourselves fortunate to be working with Immunic on this exciting project. IMU-856 is the second compound that Immunic has selected Avance Clinical as their CRO. Our engagement in these projects has been from early planning, study design, preparation of the investigator brochures and clinical trial protocols. Working with the Immunic team and the Bellberry Human Research Ethics Committee, we have been able to design clinical trials which include careful data informed adaptive elements aimed at expediting the transition of these promising products from healthy volunteers to the patient populations."
See full announcement here: https://tinyurl.com/y5rvh7fa
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. Immunic is developing three small molecule products: its lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect;IMU-935 is an inverse agonist of RORrt;and IMU-856 targets the restoration of the intestinal barrier function. On August 2, 2020, Immunic announced positive top-line results from its phase 2 EMPhASIS trial of IMU-838 in patients with relapsing-remitting multiple sclerosis, reporting achievement of both primary and key secondary endpoints with high statistical significance, indicating activity for IMU-838 in this indication. IMU-838 is also in phase 2 clinical development for ulcerative colitis and COVID-19, with an additional phase 2 trial considered in Crohn's disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic. For further information, please visit: www.imux.com.
About Avance Clinical
Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations. Avance Clinical facilitates quality drug development by aligning people, skills, and expertise in the pursuit of drug development for a healthier world.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups. Visit http://www.avancecro.com for more information.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. Telehealth pivot during COVID-19 pandemic - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons
Media Contact:
media@avancecro.com
Chris Thompson
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com
「けつぷりぷりやないかい」グラビアアイドル麻倉瑞季、レオタードでキュートなヒップライン披露
クロちゃんを騙した「レイちゃま(小林レイミ)」の現在が別人すぎると話題に
【一覧】DeNAの開幕1軍メンバーと過去10年の開幕戦結果
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
ベリシリコンの完全なBluetooth Low Energy IPソリューションが、LE Audio仕様と完全に準拠
【3月29日生まれの著名人】西島秀俊、篠原ともえ、鈴木亮平、里田まい、柏木ひなたら
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
【一覧】ソフトバンクの開幕1軍メンバーと過去10年の開幕戦結果
牛角の食べ放題専門店オープン! 肉やサイドメニューを2980円から楽しめる!
【藤枝】MF中川風希、今季初の2試合連続得点に意欲「自分のよさを出してゴールに絡みたい」
クロちゃんを騙した「レイちゃま(小林レイミ)」の現在が別人すぎると話題に
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
なぜ水原一平氏が送金できたのか? の疑問に財務省OB高橋洋一氏「難しくない。できるよ」
大谷翔平の口座に「勝手に」アクセスした水原一平氏の手口に「思い当たる節ある」二宮清純氏告白
性被害告白の元女優「女性としての喜びは断たれてしまい」「気持ちがいいと感じたこともない」
壇蜜、事務所破産報道めぐる直撃に「どうしよう、という思い」 2~3週間前に聞き「ショック」
壇蜜、所属事務所の破産手続き報道にショック「なくなるんだよと聞きました。どうしよう、と」
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
弁護士の菊間千乃氏、大谷翔平会見「嘘をついているようには見えなかった」理由「いつもより…」
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
ガーシー、またも綾野剛の暴露写真でネット歓喜「この写真見て笑っちゃう」
クロちゃんを騙した「レイちゃま(小林レイミ)」の現在が別人すぎると話題に
玉置浩二の妻、青田典子(53)の現在がとんでもない事になっていると話題に
ユーチューバーもこう氏、元彼女・成海瑠奈について赤裸々告白
ゲス不倫で干されたベッキー(35)現在の姿がとんでもないことになっていると話題に
ツチヤカレン、7月5日にメジャー2ndシングル『メーデー』リリース&TikTok Live配信決定!
城田優(35)三浦春馬ファンから誹謗中傷、酷すぎると話題に
日めくりカレンダー 『音楽家の名言~あなたの演奏を変えるメッセージ~』 『クラシックの作曲家』 6月27日 同時発売!
「知らない人多すぎ!」フロントガラスの「▲マーク」は何のため!? なんと運転時に役立つ「超便利」機能だった!
「けつぷりぷりやないかい」グラビアアイドル麻倉瑞季、レオタードでキュートなヒップライン披露
クロちゃんを騙した「レイちゃま(小林レイミ)」の現在が別人すぎると話題に
【一覧】ソフトバンクの開幕1軍メンバーと過去10年の開幕戦結果
【一覧】DeNAの開幕1軍メンバーと過去10年の開幕戦結果
何があった!?「エアコン」が想定外の壊れ具合!投稿者に話を聞いた
ベリシリコンの完全なBluetooth Low Energy IPソリューションが、LE Audio仕様と完全に準拠
【3月29日生まれの著名人】西島秀俊、篠原ともえ、鈴木亮平、里田まい、柏木ひなたら
岡本夏生(56)、1600日ぶりにブログを更新した現在が衝撃
【一覧】ロッテの開幕1軍メンバーと過去10年の開幕戦結果
【一覧】日本ハムの開幕1軍メンバーと過去10年の開幕戦結果